Food and Drug Administration Lifts Clinical Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Linked to Patient Death

Abstract

Get full access to this article

View all access options for this article.

References

Pfizer DMD Gene Therapy Team. Letter to the Duchenne Muscular Dystrophy community, sent through Parent Project Muscular Dystrophy (PPMD). September 28, 2021.. http://join.parentprojectmd.org/site/DocServer/A_Message_from_Pfizer_on_our_DMD_Clinical_Program_-_Sept.pdf (last accessed May 13, 2022 ).

Pfizer. Pfizer to open first U.S. sites in Phase 3 trial of investigational gene therapy for ambulatory patients with duchenne muscular dystrophy. April 28, 2022. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-open-first-us-sites-phase-3-trial-investigational (last accessed May 13, 2022 ).

Tessera Therapeutics. Tessera Therapeutics announces over $300M Series C financing to advance its GENE WRITING Platform. April 19, 2022. https://www.businesswire.com/news/home/20220419005210/en/Tessera-Therapeutics-Announces-Over-300M-Series-C-Financing-to-Advance-its-GENE-WRITING-Platform (last accessed May 13, 2022 ).

Astellas Pharma. Notice regarding impairment loss for products under development. April 22, 2022. https://www.astellas.com/en/news/25731 (last accessed May 13, 2022 ).

Caribou Biosciences. Caribou Biosciences announces positive initial data for CB-010 anti-CD19 allogeneic CAR-T cell therapy. May 12, 2022. https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-positive-initial-data-cb-010-anti (last accessed May 13, 2022 )

Nastoupil

, O'Brien

, Holmes

, et al. Firstin-human trial of CB-010, a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knock out, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (ANTLER Study). European Hematology Association (EHA) 2022 Library, May 12, 2022.. https://library.ehaweb.org/eha/2022/eha2022-congress/358312/loretta.j.nastoupil.first-in-human.trial.of.cb-010.a.crispr-edited.allogeneic.html (last accessed May 13, 2022 ).

REGENXBIO. REGENXBIO reports first quarter 2022 financial results and recent operational highlights. May 4, 2022. http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-reports-first-quarter-2022-financial-results-and (last accessed May 13, 2022 ).

Philippidis

Scribe pursues CRISPR therapies with expanded Biogen Collaboration. Genetic Engineering & Biotechnology News, May 12, 2022. https://www.genengnews.com/topics/genome-editing/scribe-pursues-crispr-therapies-with-expanded-biogen-collaboration/ (last accessed May 13, 2022 ).

Scribe Therapeutics. Scribe Therapeutics expands collaboration with Biogen to second target. May 2, 2022. https://www.scribetx.com/press-release-scribe-therapeutics-expands-collaboration-with-biogen-to-second-target/ (last accessed May 13, 2022 ).

10.

Apertura Gene Therapy. Apertura Gene Therapy launches with $67M Series A financing from Deerfield and an Innovative Technology Platform to develop genetic medicines. April 22, 2022.. https://aperturagtx.com/2022/04/22/apertura-gene-therapy-launches-with-67m-series-a-financing-from-deerfield-and-an-innovative-technology-platform-to-develop-genetic-medicines/ (last accessed May 13, 2022 ).